International Society on Thrombosis and Haemostasis
51 episodes
1 week ago
In this episode, we explore the evolving role of artificial intelligence in thrombosis and hemostasis with Nikola Vladic. Drawing from his personal experience with hematological malignancy and his passion for clinical research, Nikola discusses his recent study comparing the performance of AI language models, including ChatGPT, LaMDA Mistral, and DeepSeek, to thrombosis experts in clinical decision-making and patient education. The conversation dives into how these models performed and what this means for the future of medical practice. Listeners will also hear insights on the ethical implications, collaborative nature of AI-driven research and the next steps in advancing responsible innovation within thrombosis care. Read the entire study published in JTH: www.jthjournal.org/article/S1538-7836(25)00592-6/fulltext
All content for ISTH Podcasts is the property of International Society on Thrombosis and Haemostasis and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we explore the evolving role of artificial intelligence in thrombosis and hemostasis with Nikola Vladic. Drawing from his personal experience with hematological malignancy and his passion for clinical research, Nikola discusses his recent study comparing the performance of AI language models, including ChatGPT, LaMDA Mistral, and DeepSeek, to thrombosis experts in clinical decision-making and patient education. The conversation dives into how these models performed and what this means for the future of medical practice. Listeners will also hear insights on the ethical implications, collaborative nature of AI-driven research and the next steps in advancing responsible innovation within thrombosis care. Read the entire study published in JTH: www.jthjournal.org/article/S1538-7836(25)00592-6/fulltext
Late-Breakthrough Spotlight: Phase 3 Trial Results for Rurioctocog Alfa Pegol in PUPs with Hemophilia A
ISTH Podcasts
18 minutes 8 seconds
5 months ago
Late-Breakthrough Spotlight: Phase 3 Trial Results for Rurioctocog Alfa Pegol in PUPs with Hemophilia A
In this special late-breakthrough episode of the ISTH Pulse Podcast, recorded live at #ISTH2025, host Dr. Geoffrey Barnes sits down with Dr. Robert Sidonio, Jr. to discuss groundbreaking results from a Phase 3 clinical trial of rurioctocog alfa pegol in previously untreated patients (PUPs) with severe hemophilia A. Dr. Sidonio breaks down the study design, clinical outcomes, and what sets rurioctocog alfa pegol apart from other FVIII therapies. The conversation explores the potential impact on early treatment strategies, quality of life, and the future of prophylactic care in hemophilia management. Tune in for first-hand insights from one of the leading investigators in the field—and learn how these findings could help shape clinical practice for patients and families around the world.
ISTH Podcasts
In this episode, we explore the evolving role of artificial intelligence in thrombosis and hemostasis with Nikola Vladic. Drawing from his personal experience with hematological malignancy and his passion for clinical research, Nikola discusses his recent study comparing the performance of AI language models, including ChatGPT, LaMDA Mistral, and DeepSeek, to thrombosis experts in clinical decision-making and patient education. The conversation dives into how these models performed and what this means for the future of medical practice. Listeners will also hear insights on the ethical implications, collaborative nature of AI-driven research and the next steps in advancing responsible innovation within thrombosis care. Read the entire study published in JTH: www.jthjournal.org/article/S1538-7836(25)00592-6/fulltext
